AUTHOR CONTRIBUTION FORM

<table>
<thead>
<tr>
<th>Title</th>
<th>A Phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E</th>
</tr>
</thead>
<tbody>
<tr>
<td>First author</td>
<td>Sarit Assouline</td>
</tr>
</tbody>
</table>

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html):

“Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The responsible author of this manuscript confirms that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Responsible author (author responsible for the integrity of the work as a whole)
Name: Katherine L. B. Borden
Institute: Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal, Montréal, QC, Canada
e-mail: katherine.borden@umontreal.ca

Author contributions

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, interpretation of data, preparation of the text, etc.) :

SA was the principal investigator of the clinical trial. SA also contributed to the conception and design of the study as well as the drafting of the manuscript, participated in the collection and assembly of the data, recruited patients, analyzed and interpreted data. BC-K and HAZ designed, conducted, and analyzed experiments, as well as interpreted the data. EC coordinated all activities from multiple sites, contributed to the study design, drafting of the manuscript, collection, assembly, analysis and interpretation of the data. JB and SC contributed to patient recruitment. CL coordinated all activities from multiple sites and contributed to data collection and assembly. CJL contributed to data collection and assembly. WHM contributed to study design and analyzed data. KLBB was the principle investigator of the correlative studies. KLBB came up with the concept of targeting eIF4E with ribavirin in cancer, contributed to the conception and design of the study, data analysis, data assembly, interpretation of data and drafting of the manuscript. All authors revised the manuscript critically.